典型文献
Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma
文献摘要：
Primary liver cancer,mainly hepatocellular carcinoma(HCC),is the sixth most diagnosed cancer and third leading cause of cancer-related death globally.Recently,immunotherapies such as immune checkpoint in-hibitors(ICIs)have made great progress in the systemic treatment of HCC.However,anti-PD-1 therapy with pembrolizumab or nivolumab as a single agent did not meet their predefined end points of overall survival in the KEYNOTE-240 and CheckMate 459 trials.It is urgent to understand the immunological ra-tionale and explore novel ways to improve the efficacy of immunotherapy.The combination of ICIs with other therapies,such as tyrosine kinase inhibitors(TKIs),monoclonal antibodies,or local therapy,has been demonstrated to improve overall response rate and survival.In addition,modulating tumor microen-vironment is a potential way to overcome the primary and secondary resistance to immunotherapies.In this review,we summarized the latest findings in the immune microenvironment,the mechanisms of their synergistic effects when combined with anti-VEGF agents or TKIs,as well as other kinds of immune treatment.
文献关键词：
中图分类号：
作者姓名：
Ying Zhu;Lun-Xiu Qin
作者机构：
Department of General Surgery,Huashan Hospital,Cancer Metastasis Institute,Fudan University,Shanghai 200040,China;Institutes of Biomedical Sciences,Fudan University,Shanghai 200032,China
文献出处：
引用格式：
[1]Ying Zhu;Lun-Xiu Qin-.Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma)[J].国际肝胆胰疾病杂志(英文版),2022(05):420-429
A类：
tionale,microen
B类：
Strategies,improving,efficacy,immunotherapy,hepatocellular,carcinoma,Primary,liver,cancer,mainly,HCC,sixth,most,diagnosed,third,leading,cause,related,death,globally,Recently,immunotherapies,such,immune,checkpoint,ICIs,have,made,great,progress,systemic,treatment,However,pembrolizumab,nivolumab,single,did,meet,their,predefined,end,points,overall,survival,KEYNOTE,CheckMate,trials,It,urgent,understand,immunological,explore,novel,ways,improve,combination,tyrosine,kinase,inhibitors,TKIs,monoclonal,antibodies,local,has,been,demonstrated,response,In,addition,modulating,tumor,potential,overcome,primary,secondary,resistance,this,review,summarized,latest,findings,microenvironment,mechanisms,synergistic,effects,when,combined,VEGF,agents,well,kinds
AB值：
0.587746
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
